Physician profile
Eric D Jaggers
NPI 1902954357
$260,352.69
in general payments reported to CMS, 2019-2025
21 companies · $28K in 2025
The $28K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $23K · 2021: $37K · 2022: $28K · 2023: $33K · 2024: $30K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $82K · Food and Beverage: $5,742 · Travel and Lodging: $2,686 · Consulting Fee: $460 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,774.75 |
| Food and Beverage | $5,741.86 |
| Travel and Lodging | $2,686.42 |
| Consulting Fee | $460.00 |
| Education | $123.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $84,383.45 | 2019-2025 | Aristada, Aristada Initio, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $74,568.55 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $71,732.10 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $12,466.71 | 2019-2025 | Invega Sustenna, Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $7,887.40 | 2020-2025 | Caplyta |
| Allergan, INC. | $2,969.09 | 2019-2020 | |
| Abbvie INC. | $1,767.91 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $1,192.05 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $912.03 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $674.36 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $589.60 | 2019-2025 | Fanapt, Hetlioz |
| Indivior INC. | $277.54 | 2019-2024 | Perseris |
| Axsome Therapeutics, INC. | $248.98 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $246.57 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $103.16 | 2024-2025 | Secuado |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $93.03 | 2020-2022 | |
| Eisai INC. | $75.99 | 2020-2021 | |
| Almatica Pharma LLC | $58.50 | 2023-2024 | Loreev Xr |
| Tris Pharma INC | $45.02 | 2024-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $43.76 | 2022-2024 | Quviviq |
| Acadia Pharmaceuticals INC | $16.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Jaggers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.